Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
Go back to Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.97 +0.95 (5.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.02 | 52 Week High | $63.73 | |||
| Open | $17.50 | 52 Week Low | $8.00 | |||
| Day High | $18.19 | P/E | N/A | |||
| Day Low | $16.90 | EPS | $-5.69 | |||
| Volume | 4,213,972 | |||||
